Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway
Autor: | Jun Peng, Jie Yang, Yue-Qi Li, Yi-Yue Zhang, Wei-Ning Liu, Xiao-Jie Zhang, Xiu-Ju Luo |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Ligustroflavone Cell Survival Necroptosis Ischemia Pharmacology PC12 Cells Rats Sprague-Dawley 03 medical and health sciences RIPK1 0302 clinical medicine Downregulation and upregulation Animals Medicine Glycosides Apigenin Protein kinase A Stroke business.industry Brain Infarction Middle Cerebral Artery General Medicine Rat brain medicine.disease Rats Neuroprotective Agents 030104 developmental biology Receptor-Interacting Protein Serine-Threonine Kinases business Protein Kinases 030217 neurology & neurosurgery Signal Transduction |
Zdroj: | Naunyn-Schmiedeberg's Archives of Pharmacology. 392:1085-1095 |
ISSN: | 1432-1912 0028-1298 |
DOI: | 10.1007/s00210-019-01656-9 |
Popis: | Receptor-interacting protein kinase 1/3 (RIPK1/3) and mixed lineage kinase domain-like (MLKL)-mediated necroptosis contributes to brain injury after ischemic stroke. Ligustroflavone is an ingredient of common privet with activities of anti-inflammation and complement inhibition. This study aims to explore the effect of ligustroflavone on ischemic brain injury in stroke rat and the underlying mechanisms. A rat model of ischemic stroke was established by middle cerebral artery occlusion (MCAO), which showed ischemic injury (increase in neurological deficit score and infarct volume) and upregulation of necroptosis-associated proteins (RIPK1, RIPK3 and MLKL/p-MLKL). Administration of ligustroflavone (30 mg/kg, i.g.) 15 min before ischemia evidently improved neurological function, reduced infarct volume, and decreased the levels of necroptosis-associated proteins except the RIPK1. Consistently, hypoxia-cultured PC12 cells (O2/N2/CO2, 1:94:5, 8 h) caused cellular injury (LDH release and necroposis) concomitant with up-regulation of necroptosis-associated proteins, and these phenomena were blocked in the presence of ligustroflavone (25 μM) except the elevated RIPK1 levels. Using the Molecular Operating Environment (MOE) program, we identified RIPK1, RIPK3, and MLKL as potential targets of ligustroflavone. Further studies showed that the interaction between RIPK3 and RIPK1 or MLKL was significantly enhanced, which was blocked in the presence of ligustroflavone. Based on these observations, we conclude that ligustroflavone protects rat brain from ischemic injury, and its beneficial effect is related to the prevention of necroptosis through a mechanism involving targeting RIPK1, RIPK3, and/or MLKL. |
Databáze: | OpenAIRE |
Externí odkaz: |